Watch CBS News

​Teva stops selling migraine patch after reports of burns

Microsoft is buying LinkedIn in a $26.2 billion all-cash deal; Tony winner Hamilton could generate $1 billion in sales; and Apple wants a better Siri
Microsoft buying LinkedIn, and other MoneyWatch headlines 01:05

NEW YORK - Teva Pharmaceutical says it will stop selling its migraine patch treatment Zecuity after users reported burns and scars where it was applied.

The company says anyone who has a patch should not use it.

Zecuity is a disposable battery-powered patch that is applied to the upper arm or thigh to ease migraine headaches. The patch delivers medicine through the skin.

The U.S. Food and Drug Administration says some users reported severe redness, skin discoloration, cracked skin and pain where the patch was applied.

Teva, based in Israel, says it is recalling Zecuity from pharmacies and is working with the FDA to figure out what is causing the skin reactions.

Shares of Teva Pharmaceutical Industries Ltd. (TEVA) rose 54 cents to $53.55 in Monday morning trading.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.